What should I do if I experience skipped beats after discontinuing a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Skipped Beats After Discontinuing SNRI

If you experience skipped beats (palpitations) after discontinuing an SNRI, this is likely part of SNRI discontinuation syndrome, which requires immediate medical evaluation to rule out cardiac complications, followed by consideration of restarting the medication with a slower taper. 1

Understanding SNRI Discontinuation Syndrome

SNRI discontinuation syndrome is a well-recognized phenomenon that occurs when these medications are stopped abruptly or tapered too quickly. 1 The syndrome includes:

  • Autonomic symptoms: Increased blood pressure, increased pulse, tachycardia, diaphoresis (sweating), shivering 1
  • Cardiovascular symptoms: Palpitations (skipped beats), arrhythmias 1
  • Physical symptoms: Dizziness, headache, nausea, vomiting, diarrhea, fatigue, lethargy, myalgias 1
  • Neurological symptoms: Sensory disturbances, paresthesias (electric shock sensations), tremor, imbalance, vertigo 1
  • Psychological symptoms: Anxiety, irritability, agitation, insomnia, confusion 1

Symptoms typically emerge within a few days of discontinuation and can last several weeks, though late onset and longer persistence can occur. 2, 3

Immediate Clinical Action Required

You need urgent medical evaluation to distinguish discontinuation syndrome from potentially serious cardiac arrhythmias. 1 Your clinician should:

  • Obtain an ECG to evaluate for actual arrhythmias, QT prolongation, or other cardiac abnormalities 1
  • Monitor vital signs including pulse and blood pressure, as SNRIs can cause sustained hypertension and increased pulse 1
  • Assess for serotonin syndrome features (though less likely after discontinuation): mental status changes, neuromuscular hyperactivity (tremors, clonus, hyperreflexia), and autonomic hyperactivity (hypertension, tachycardia, arrhythmias) 1

Management Strategy

The recommended approach is to restart the SNRI at the previously prescribed dose to resolve symptoms, then implement a much slower tapering schedule. 1, 4

Reinitiation and Gradual Taper

  • Resume the previously prescribed SNRI dose if symptoms are intolerable 4
  • Once symptoms resolve, begin a gradual dose reduction rather than abrupt cessation 1
  • Use non-linear dose-reduction steps (smaller decrements as you approach lower doses) if you have risk factors for withdrawal 5
  • Adjust the tapering speed based on emergence of symptoms 5

Risk Factors for Severe Discontinuation Symptoms

You are at higher risk for discontinuation syndrome if: 5

  • You experienced withdrawal symptoms with missed doses or non-compliance previously
  • A previous attempt to stop was unsuccessful
  • You were taking higher than the smallest effective dose
  • You were taking venlafaxine (which has higher prevalence of withdrawal symptoms compared to other SNRIs) 2

Important Caveats

Venlafaxine has been specifically associated with more severe discontinuation symptoms and overdose fatalities compared to other SNRIs. 1 If you were taking venlafaxine, extra caution is warranted.

The sensation of "skipped beats" could represent: 1

  • Benign premature atrial or ventricular contractions (common in discontinuation syndrome)
  • Actual arrhythmias requiring treatment
  • Heightened awareness of normal heartbeat variations due to anxiety from discontinuation

Do not attempt to manage this on your own—medical supervision is essential for both cardiac evaluation and safe medication tapering. 1, 4

Monitoring During Taper

When restarting and tapering, your clinician should monitor: 1

  • Height, weight, pulse, and blood pressure at each visit
  • Emergence of physical symptoms (dizziness, sensory disturbances, GI symptoms)
  • Psychological symptoms (anxiety, irritability, mood changes)
  • Cardiac symptoms (palpitations, chest discomfort)

The gradual tapering approach minimizes risk of discontinuation symptoms, though the long elimination half-lives of some SNRIs (duloxetine, venlafaxine extended-release, desvenlafaxine) may provide some natural protection. 1

References

Related Questions

Are SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) discontinuation symptoms dangerous or just uncomfortable?
Do you need to taper off sertraline (Selective Serotonin Reuptake Inhibitor) to start an SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)?
How should Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) be discontinued to minimize discontinuation side effects?
Can a Selective Serotonin Reuptake Inhibitor (SSRI) be started while tapering off an existing one?
Can I start Pristiq (desvenlafaxine) at 25mg while discontinuing Luvox (fluvoxamine)?
What is the preferred treatment, Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine (Prozac) or psychostimulants like modafinil (Provigil), for hypnagogic hallucinations and sleep paralysis?
What is the comparative efficacy and safety of dupilumab (anti-IL-4/IL-13 monoclonal antibody) vs high-dose Proton Pump Inhibitors (PPIs) as first-line, and topical corticosteroids (such as oral budesonide or fluticasone) and empiric Food Elimination Diet (FED) as second-line treatments for Eosinophilic Esophagitis (EoE)?
What is the most likely substance ingested by a patient presenting with anticholinergic toxidrome, including dry mucous membranes, dilated pupils, and altered mental status, with a history of depression, anxiety, and chronic back pain?
What is the plan of care for a patient with hyperlipidemia?
What is the efficacy of selective serotonin reuptake inhibitors (SSRIs) or psychostimulants for treating sleep paralysis?
What is the recommended dosing for linezolid when transitioning from vancomycin and meropenem for treating leukocytosis of unknown origin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.